Lauren G. Grau

LAUREN GRAU advises emerging and public companies, private equity firms and individuals on a range of technology and intellectual property-related issues in connection with mergers, acquisitions, divestitures, joint ventures, collaborations, licenses, strategic investments, financing transactions and services agreements. Her practice focuses on representing clients in the life sciences, healthcare, energy, information technology, software, telecommunications, aviation and consumer products sectors. Lauren leverages her training in biochemistry and her prior engineering and patent litigation experience while advising her clients on their business and transactional matters.

Lauren was recently named a “Rising Star” in the 2023–2024 editions of LMG Life Sciences for Licensing and Collaboration, in the Financial & Corporate section. She was also recognized by D Magazine as a “Best Lawyer in Dallas” in 2020, 2024, and 2025 for Corporate Law: Technology Transactions. In 2010, Lauren received the “Outstanding Young Associate Award” for her pro bono work with the Human Rights Initiative of North Texas. 

Before attending law school, Lauren worked for five years for a leading competitive local exchange carrier as a telecommunications engineer. While attending law school, Lauren interned with the Honorable Harlin D. Hale at the United States Bankruptcy Court for the Northern District of Texas and served as head casenotes & comments editor of the Houston Journal of International Law for 2007–2008.

Transactional Experience: Life Sciences, Healthcare

• DaVita Inc., a leading provider of kidney care services, in its agreement to expand its international operations in Brazil and Colombia and its entry into Chile and Ecuador.
• Hoffmann La-Roche in its acquisition of Carmot Therapeutics Inc., a clinical-stage biotechnology company dedicated to developing therapeutics for people living with metabolic diseases, for an upfront payment of US$2.7 billion and additional milestone payments of up to US$400 million.
• Novant Health, Inc. in its agreement with Tenet Healthcare Corporation (NYSE: THC) to acquire three Tenet hospitals and affiliated operations in South Carolina for approximately US$2.4 billion.
• Myovant Sciences in its exclusive licensing agreement with Accord Healthcare, Ltd., to commercialize relugolix for the treatment of advanced, hormone-sensitive prostate cancer in the European Economic Area, United Kingdom, Switzerland, and Turkey.
• DaVita Inc. in its joint venture with Medtronic to form a new, independent, kidney care-focused medical device company. The new company will focus on developing a broad suite of novel kidney care products and solutions, including future home-based products, to make different dialysis treatments more accessible to patients.
• OMERS Private Equity in its agreement to sell its interest in Forefront Dermatology to global private markets firm Partners Group.
• CA Healthcare Acquisition Corp., a special purpose acquisition company focused on investing in a growth-oriented healthcare company, in its pending business combination with LumiraDx Limited, a next-generation point of care diagnostics testing company. The transaction has an implied pro forma equity value of US$3 billion.
• Steward Health Care System LLC in its sale of five hospitals and related hospital operations in Utah to HCA Healthcare, Inc.
• Steward Health Care System LLC in its acquisition of Tenet Healthcare Corporation’s five hospitals and related hospital operations in Florida’s Miami-Dade and southern Broward counties for approximately US$1.1 billion.
• Atomwise, a leader in using artificial intelligence (AI) for small molecule discovery, in a research collaboration agreement with Bridge Biotherapeutics (KOSDAQ: 288330), a clinical stage biotech company, to launch up to 13 small molecule programs across multiple therapeutic areas using structure-based AI technology for drug discovery.
• Yuhan Corporation in its joint development and licensing agreement with Boehringer Ingelheim, for the development of dual agonist innovative drugs with the activity of GLP-1 and FGF21 to treat nonalcoholic steatohepatitis (NASH) and related liver disease.
• Yuhan Corporation in its licensing and collaboration agreement with Gilead Sciences, Inc. to co-develop novel therapeutic candidates for the treatment of patients with advanced fibrosis due to NASH.
• Yuhan Corporation in its licensing agreement with Janssen, a division of Johnson & Johnson, for the development, manufacturing and commercialization of lazertinib, a non-small cell lung cancer drug candidate.
• Nektar Therapeutics in its in multi-billion dollar global strategic development and commercialization collaboration with Bristol-Myers Squibb Company (NYSE: BMY) for Nektar’s CD122-biased agonist, NKTR-214. Under the terms of the agreement, the companies will jointly develop and commercialize NKTR-214 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) in more than 20 indications across nine tumor types—including melanoma, renal cell carcinoma, non-small cell lung cancer, bladder and triple negative breast cancer—as well as potential combinations with other anti-cancer agents from either of the respective companies and/or third parties.
• Flatiron Health in its inaugural M&A transaction to acquire Protocol First, a software solutions provider focused on accelerating clinical research.
• Hoffman La-Roche in its acquisition of Ignyta, Inc. (NASDAQ: RXDX), a cancer therapy company, for US$1.7 billion in cash.
• GlaxoSmithKline (GSK) on a novel public-private joint venture and collaboration with the University of North Carolina at Chapel Hill dedicated to seeking a cure for HIV. GSK will invest US$4 million in the partnership each year during the five-year research agreement.
• Genentech, a member of the Roche Group, in its agreement to acquire Seragon Pharmaceuticals, Inc., a biotechnology company focused on selective estrogen receptor degraders to treat hormone receptor-positive breast cancer, for a total amount of up to US$1.7 billion.
• Roche Molecular Systems in its acquisition of Genia Technologies, Inc., a DNA sequencing company, for up to US$350 million, and its acquisition of Bina Technologies Inc., the creator of a big data platform for managing and processing next generation sequencing data.

Transactional Experience: Energy, Information Technology, Telecommunications, Consumer Products, Other

• Texon, L.P., a Houston, Texas-based midstream service provider of butane blending and energy marketing, in its sale to Savage, a global provider of supply chain infrastructure and solutions.
• Enbridge Inc. in an infrastructure development agreement with Divert Inc. to develop projects turning wasted food into renewable natural gas (RNG) across the U.S. for up to more than US$1 billion of capital investments underpinned by long-term, take-or-pay contracts.
• National Western in its US$1.9 billion acquisition by an affiliate of Prosperity Life.
• Fleming Insurance Holdings, a portfolio company of Altamont Capital Partners, in its strategic US$277 million acquisition of JRG Reinsurance Company (JRG Re).
• Darling Ingredients Inc. in its US$1.1 billion acquisition of Valley Proteins.
• Cresta Fund Management and Silverpeak Energy Partners in their agreement with San Joaquin Renewables to invest up to US$165 million to develop and construct a biomass-to-renewable natural gas project near McFarland, California.
• Enbridge, Inc. in its transaction with Encap Flatrock Midstream to acquire Moda Midstream Operating, LLC for US$3 billion in cash.
• American National Group, Inc. as lead transaction counsel in its acquisition by Brookfield Asset Management Reinsurance Partners Ltd. in a transaction valued at US$5.1 billion.
• Bodega Latina Corporation in its acquisition of Smart & Final Holdings, Inc. from funds managed by affiliates of Apollo Global Management, Inc. (NYSE:APO) for approximately US$620 million. Bodega Latina is a subsidiary of Grupo Comercial Chedraui, S.A.B. de C.V.
• AmeriHome Mortgage Company, LLC (AmeriHome) in the sale of AmeriHome by subsidiaries of Athene Holding Ltd. (NYSE:ATH) and funds affiliated with Apollo Global Management to Western Alliance Bancorporation.
• EQT Partners Inc. in connection with the merger of its portfolio company, FocusVision, with Confirmit, a portfolio company of Verdane.
• Safe Harbor Marinas in its sale to Sun Communities, Inc., a publicly traded REIT focused on manufactured housing and recreational vehicle communities, in a transaction for cash and equity valued at US$2.11 billion.
• Eagle Materials Inc. in the sale of its Western Aggregates and Mathews Readymix operations to Teichert, a California-based construction company, for US$93.5 million.
• HMS in the acquisition of Accent, a payment accuracy and cost containment business, from Intrado Corporation for US$155 million.
• TSG Consumer Partners and its portfolio companies in numerous matters, including the US$1.2 billion sale of portfolio company IT Cosmetics, LLC to L’Oreal.
• Siris Capital Group, LLC in its US$654 million acquisition of Xura, Inc. (formerly Comverse).
• KPMG, OMERS Private Equity, Dell, R.R. Donnelley & Sons Company, FLIR Systems, Inc., Thompson Street Capital Partners and a number of private equity funds in M&A and financing transactions.

• State Bar of Texas, Member
• Dallas Bar Association, Member
• DFW Women in IP